Clearside Biomedical (NASDAQ:CLSD – Get Free Report) will be posting its quarterly earnings results after the market closes on Monday, November 13th. Analysts expect Clearside Biomedical to post earnings of ($0.16) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last announced its earnings results on Monday, August 14th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Clearside Biomedical had a negative net margin of 2,217.30% and a negative return on equity of 533.87%. The company had revenue of $1.02 million during the quarter, compared to analysts’ expectations of $0.21 million. On average, analysts expect Clearside Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Clearside Biomedical Trading Up 16.3 %
Shares of CLSD stock opened at $0.97 on Friday. The business’s 50 day moving average is $0.85 and its two-hundred day moving average is $1.02. Clearside Biomedical has a twelve month low of $0.65 and a twelve month high of $1.85. The company has a market capitalization of $60.06 million, a P/E ratio of -1.64 and a beta of 2.17.
Analyst Ratings Changes
Insider Activity at Clearside Biomedical
In other news, major shareholder Bradford T. Whitmore bought 64,366 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were bought at an average cost of $0.74 per share, for a total transaction of $47,630.84. Following the completion of the transaction, the insider now owns 4,050,590 shares in the company, valued at $2,997,436.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired a total of 84,966 shares of company stock worth $65,245 over the last three months. 9.80% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Clearside Biomedical
A number of institutional investors have recently made changes to their positions in CLSD. Balyasny Asset Management LLC acquired a new position in shares of Clearside Biomedical in the third quarter worth $25,000. Mackenzie Financial Corp acquired a new position in Clearside Biomedical in the first quarter valued at $27,000. JPMorgan Chase & Co. increased its stake in Clearside Biomedical by 100.6% in the second quarter. JPMorgan Chase & Co. now owns 18,161 shares of the company’s stock valued at $27,000 after purchasing an additional 9,109 shares during the last quarter. Stifel Financial Corp increased its stake in Clearside Biomedical by 375.6% in the second quarter. Stifel Financial Corp now owns 60,544 shares of the company’s stock valued at $68,000 after purchasing an additional 47,814 shares during the last quarter. Finally, XTX Topco Ltd increased its stake in Clearside Biomedical by 125.6% in the first quarter. XTX Topco Ltd now owns 50,947 shares of the company’s stock valued at $117,000 after purchasing an additional 28,366 shares during the last quarter. 13.70% of the stock is owned by institutional investors and hedge funds.
About Clearside Biomedical
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.
- Five stocks we like better than Clearside Biomedical
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Data giants MongoDB and Snowflake just got upgraded
- Financial Services Stocks Investing
- Plug Power at tipping point; it’s make or break time for hydrogen
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.